Strados Labs


Contact Nick Delmonico
Title Co-Founder


Summary: Strados Labs makes the first and only always-on health device and platform that combines heart and lung data so doctors can make informed decisions for asthma and COPD patients. Strados pairs real-time respiratory data with a multitude of external features including activity level, heart rate, altitude, medications, pollen and temperature. This enables physicians to create more personalized management plans for their patients, which may improve medication compliance, self-monitoring and quality of life. Strados bridges the data gap for chronic respiratory patients who aim to better understand breathing patterns and enables positive behavioral change using the Strados platform. The Strados solution was designed with users in mind, with a contoured shape to allow for various torso sizes and textures. In the U.S. market, new regulations are expanding the use of remote devices like Strados to monitor a variety of chronic diseases. For the first time, providers will be able to bill for the time they spend reviewing patient-generated health data from devices like Strados. This presents a major market opportunity for Strados as the first remote respiratory wearable in the country. Health organizations can also benefit from the long-term impact of reducing readmissions or hospitalizations due to asthma through our powerful predictive platform.
Need: The Global Burden of Disease Study (GBD) estimates the number of people affected by asthma worldwide to be 334 million, which is approximately 5% of the world population.  According to the Center for Disease Control (CDC), approximately 1 in 12 children in the United States have asthma. Nearly 3 of every 5 children with asthma had an asthma attack in 2013. In 2007, the economic burden of asthma attacks across all patients in the U.S was roughly $56 billion.  The cost of asthma attacks derive from increase in health care utilization, particularly acute care, as well as lost workdays by caregivers.
Value: Strados Labs offers a patent-pending end-to-end solution uniquely addressing the challenge of recognizing signs and symptoms of asthma, tracking respiratory health trends and effectively communicating these trends back to providers.  Strados unique value proposition lies in its ability to collect all the key physiologic data in a single user friendly platform, thus enhancing respiratory disease management by patients and clinicians, while offering key data and savings for payers.

Company News

Who won the INVEST Digital Health Pitch Perfect contest? feat. Strados Labs

DateSep 27, 2021
The INVEST Digital Health Pitch Perfect contest spotlighted 18 companies across three categories: home health, chronic disease management and value-based care, and technology to support payer and provider efficiency.
Read More →

Strados Labs receives FDA 510(k) clearance for its wireless lung sound measurement platform, RESP™

DateDec 22, 2020
Strados Labs, a health technology developer of remote respiratory devices and software, today announced it has received FDA Class II 510(k) clearance for its first product, RESP™, a system for measuring, recording and analyzing lung sounds remotely across healthcare settings.
Read More →

Money Moves: 3 life science and health IT companies raise funds — and one goes public (featuring Strados Labs)

DateAug 20, 2020
Strados Labs has been awarded a National Science Foundation (NSF)Phase I Small Business Innovation Research grant for nearly $225,000 to conduct research on its wearable platform for remote respiratory monitoring.
Read More →